Pharma

Your Article Summary

See Latest Articles

Cellcept® and a reduced level of cni shows trend towards preservation of kidney function versus a standard-dose CNI
Roche, 06/05/08

The 12-month results from a multicenter trial monitoring CellCept® (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation was presented today at the American Transplant Congress (ATC). The study results showed that a reduced level of CNI with a therapeutic monitored dose of CellCept is not inferior to that of a fixed dose of CellCept, and the standard-dose of CNI as it relates to biopsy-proven acute rejection (BPAR) and other end points.

Today in Physician/Patient Trends...keeping you current

Receive free subspecialty "5-minute updates" via email

New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09

Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09

Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09

 See all of Physician/Patient Trends